e11540 Background: Metastatic breast cancer is a heterogenous disease. There are several subgroups according to pathological, biological and molecular behaviours of the tumor. Recurrent metastatic breast carcinoma (RMBC) and upfront metastatic breast carcinoma (UMBC) may differ according to clinical and prognostic characteristics. Intrinsic genetic heterogeneity may be responsible for these differences. To date, little is known about the clinical features and outcome of patients with UMBC. Methods: Patients were considered to have UMBC if patients were admitted to the clinics with stage IV disease. Patients were considered to have RMBC if metastases had developed during followup for localized breast carcinoma. Between September 2007 and May 2011, 102 of 2478 (4.1%) UMBC patients who was admitted to Department of Medical Oncology Clinic, was included in this retrospective trial. Patients’ characteristics, treatment schedules and survival data were evaluated. Results: All patients were female. Median age was 50.0 (range: 26-90). More than half of patients (58.8%) were postmenopausal. Frequent histological type was invasive ductal carcinoma (89.2%). Most of the patients had grade 3 (57.8%) tumor. Hormone receptor (HR) and HER2 positivity were76.5% and 42.2%, respectively. Metastatic sites were visceral, isolated bone-soft tissue and combination in 20%, 42% and 37%, respectively. Most of visceral metastatic patients were HR negative and HER2 positive. Median PFS and OS were 30 and 66 months, respectively. Both PFS and OS were affected from HR status, HER2 status, sites of metastatic disease and chemotherapy (log-rank p=0.006, 0.04, 0.02, 0.004, 0.03 and log-rank p= 0.04, 0.04, 0.01, 0.03, 0.01 respectively). Both PFS and OS were not affected by age, menopausal status, performance status, histology and grade of the tumor. OS were longest in patients group who received chemotherapy (76 months) and shortest in patients group who received chemotherapy and targeted therapy combinations (23 months). Conclusions: Factors affecting survival were comparable to previous studies in UMBC patient population similiar to results RMBC studies. This finding should be confirmed with prospective trials in larger study populations.
Cytologic assessment of estrogen receptor, progesterone receptor, and HER2 status in metastatic breast carcinoma
